BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36916190)

  • 1. Abemaciclib drives the therapeutic differentiation of acute myeloid leukaemia stem cells.
    Xie X; Zhang W; Zhou X; Ye Z; Wang H; Qiu Y; Pan Y; Hu Y; Li L; Chen Z; Yang W; Lu Y; Zou S; Li Y; Bai X
    Br J Haematol; 2023 Jun; 201(5):940-953. PubMed ID: 36916190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML.
    Li Z; Wang F; Tian X; Long J; Ling B; Zhang W; Xu J; Liang A
    J Exp Clin Cancer Res; 2021 Jun; 40(1):210. PubMed ID: 34167558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
    Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
    J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA MAGI2-AS3 inhibits the self-renewal of leukaemic stem cells by promoting TET2-dependent DNA demethylation of the LRIG1 promoter in acute myeloid leukaemia.
    Chen L; Fan X; Zhu J; Chen X; Liu Y; Zhou H
    RNA Biol; 2020 Jun; 17(6):784-793. PubMed ID: 32174258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax.
    Gaur T; Poddutoori R; Khare L; Bagal B; Rashmi S; Patkar N; Tembhare P; Pg S; Shetty D; Dutt A; Zhang Q; Konopleva M; Platzbeckar U; Gupta S; Samajdar S; Ramchandra M; Khattry N; Hasan SK
    J Exp Clin Cancer Res; 2023 Jul; 42(1):186. PubMed ID: 37507802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.
    Paczulla AM; Rothfelder K; Raffel S; Konantz M; Steinbacher J; Wang H; Tandler C; Mbarga M; Schaefer T; Falcone M; Nievergall E; Dörfel D; Hanns P; Passweg JR; Lutz C; Schwaller J; Zeiser R; Blazar BR; Caligiuri MA; Dirnhofer S; Lundberg P; Kanz L; Quintanilla-Martinez L; Steinle A; Trumpp A; Salih HR; Lengerke C
    Nature; 2019 Aug; 572(7768):254-259. PubMed ID: 31316209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells.
    Cho H; Jang JE; Eom JI; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
    Exp Hematol Oncol; 2021 Apr; 10(1):28. PubMed ID: 33858507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
    Zhang L; Zhou Y; Chen K; Shi P; Li Y; Deng M; Jiang Z; Wang X; Li P; Xu B
    Target Oncol; 2017 Oct; 12(5):677-687. PubMed ID: 28710745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclax.
    Ye S; Xiong F; He X; Yuan Y; Li D; Ye D; Shi L; Lin Z; Zhao M; Feng S; Zhou B; Weng H; Hong L; Ye H; Gao S
    Theranostics; 2023; 13(1):77-94. PubMed ID: 36593968
    [No Abstract]   [Full Text] [Related]  

  • 10. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
    Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
    Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance.
    Ly M; Rentas S; Vujovic A; Wong N; Moreira S; Xu J; Holzapfel N; Bhatia S; Tran D; Minden MD; Draper JS; Hope KJ
    Cancer Res; 2019 Nov; 79(22):5799-5811. PubMed ID: 31519687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia.
    Luedtke DA; Su Y; Ma J; Li X; Buck SA; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Lin H; Taub JW; Ge Y
    Signal Transduct Target Ther; 2020 Feb; 5(1):17. PubMed ID: 32296028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.
    Yoshimoto G; Miyamoto T; Jabbarzadeh-Tabrizi S; Iino T; Rocnik JL; Kikushige Y; Mori Y; Shima T; Iwasaki H; Takenaka K; Nagafuji K; Mizuno S; Niiro H; Gilliland GD; Akashi K
    Blood; 2009 Dec; 114(24):5034-43. PubMed ID: 19808698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia.
    Sachs K; Sarver AL; Noble-Orcutt KE; LaRue RS; Antony ML; Chang D; Lee Y; Navis CM; Hillesheim AL; Nykaza IR; Ha NA; Hansen CJ; Karadag FK; Bergerson RJ; Verneris MR; Meredith MM; Schomaker ML; Linden MA; Myers CL; Largaespada DA; Sachs Z
    Cancer Res; 2020 Feb; 80(3):458-470. PubMed ID: 31784425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tracing the origins of relapse in acute myeloid leukaemia to stem cells.
    Shlush LI; Mitchell A; Heisler L; Abelson S; Ng SWK; Trotman-Grant A; Medeiros JJF; Rao-Bhatia A; Jaciw-Zurakowsky I; Marke R; McLeod JL; Doedens M; Bader G; Voisin V; Xu C; McPherson JD; Hudson TJ; Wang JCY; Minden MD; Dick JE
    Nature; 2017 Jul; 547(7661):104-108. PubMed ID: 28658204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
    Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
    Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.
    Kawabata KC; Zong H; Meydan C; Wyman S; Wouters BJ; Sugita M; Goswami S; Albert M; Yip W; Roboz GJ; Chen Z; Delwel R; Carroll M; Mason CE; Melnick A; Guzman ML
    Blood; 2021 Feb; 137(6):812-825. PubMed ID: 32911532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation.
    Opydo M; Mlyczyńska A; Mlyczyńska E; Rak A; Kolaczkowska E
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of Kat2a enhances transcriptional noise and depletes acute myeloid leukemia stem-like cells.
    Domingues AF; Kulkarni R; Giotopoulos G; Gupta S; Vinnenberg L; Arede L; Foerner E; Khalili M; Adao RR; Johns A; Tan S; Zeka K; Huntly BJ; Prabakaran S; Pina C
    Elife; 2020 Jan; 9():. PubMed ID: 31985402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non-coding RNA HOTAIR regulates myeloid differentiation through the upregulation of p21 via miR-17-5p in acute myeloid leukaemia.
    Hu L; Liu J; Meng Y; Zheng H; Ding C; Wang H; Charwudzi A; Li M; Li J; Zhai Z; Xiong S
    RNA Biol; 2021 Oct; 18(10):1434-1444. PubMed ID: 33241756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.